Floatz logo

Sargramostim

Recurrent Melanoma

Mayo Clinicprotein_peptidePhase 3Active
BBB
72/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
61/ 100
Competitive Position
95/ 100

Competitive context

449 Active assets in the Recurrent Melanoma cohort.

Asset / SponsorPhaseRating
Gm-Csf
Ultimovacs ASA
Phase 4BBB
Cediranib
M.D. Anderson Cancer Center
Phase 3BBB
Ifa
Craig L Slingluff, Jr
Phase 2BB
DACARBAZINE
Suzhou BlueHorse Therapeutics Co., Ltd.
Phase 3BB
Temsirolimus
University of Regensburg
Phase 2BB

View all 50 →

Same molecule, other indications

Sargramostim is also rated in:

chronic myeloid leukemiaDormant
BBB
Indicative ·
72 / 100
View asset →
cancer of unknown primary siteDormant
BBB
Indicative ·
72 / 100
View asset →
acute myeloid leukemiaDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →